TG THERAPEUTICS
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 264
- Market Cap
- $3.5B
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT02006485
- Locations
- ๐บ๐ธ
TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01767766
- Locations
- ๐บ๐ธ
TG Therapeutics Trial Site, Nashville, Tennessee, United States
๐บ๐ธTG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01744912
- Locations
- ๐บ๐ธ
TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01647971
- Locations
- ๐บ๐ธ
TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath